HGF/c-met system targeting PI3K/AKT and STAT3/phosphorylated-STAT3 pathways in pituitary adenomas: An immunohistochemical characterization in view of targeted therapies

Endocrine

Volumn 44, Issue 3, 2013, Pages 735-743

  Trovato, Maria ^a   Torre, Maria Luisa ^a   Ragonese, Marta ^a   Simone, Angela ^a   Scarfì, Rosy ^a   Barresi, Valeria ^a   Giuffrè, Giuseppe ^a   Benvenga, Salvatore ^a   Angileri, Flavio F ^b   Tuccari, Giovanni ^a   Trimarchi, Francesco ^a   Ruggeri, Rosaria Maddalena ^a   Cannavò, Salvatore ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

HGF c met signaling; pAKT; PI3K; Pituitary adenomas; STAT3 pSTAT3

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; STAT3 PROTEIN;

ADULT; AGED; ALPHA CHAIN; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR VOLUME; YOUNG ADULT;

ADENOMA; ADOLESCENT; ADULT; AGED; ENDOTHELIAL CELLS; FEMALE; HEPATOCYTE GROWTH FACTOR; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PITUITARY NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MET; STAT3 TRANSCRIPTION FACTOR;

EID: 84890798825     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-013-9950-x     Document Type: Article

References (48)

1. N.O. Schmidt, M. Westphal, C. Hagel, S. Ergün, D. Stavrou, E.M. Rosen, K. Lamszus, Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis. Int. J. Cancer 84, 10-18 (1999)
2. C. Birchmeier, W. Birchmeier, E. Gherardi, G.F. Vande Woude, Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol. 4, 915-925 (2003)
3. E. Gherardi, M.E. Youles, R.N. Miguel, T.L. Blundell, L. Iamele, J. Gough, A. Bandyopadhyay, G. Hartmann, P.J. Butler, Functional map and domain structure of MET, the product of the c-met protooncogene and receptor for hepatocyte growth factor/scatter factor. PNAS 100, 12039-12044 (2003)
4. W.G. Jiang, T.A. Martin, C. Parr, G. Davies, K. Matsumoto, T. Nakamura, Hepatocyte growth factor, its receptor, and their potential value in cancer therapies. Crit. Rev. Oncol. Hematol. 53, 35-69 (2005)
5. R. Abounader, J. Laterra, Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro Oncol. 7, 436-451 (2005)
6. M. Delehedde, N. Sergeant, M. Lyon, P.S. Rudland, D.G. Fernig, Hepatocyte growth factor/scatter factor stimulates migration of rat mammary fibroblasts through both mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt pathways. Eur. J. Biochem. 268, 4423-4429 (2001)
7. H. Nakagami, R. Morishita, K. Yamamoto, Y. Taniyama, M. Aoki, K. Matsumoto, T. Nakamura, Y. Kaneda, M. Horiuchi, T. Ogihara, Mitogenic and antiapoptotic actions of hepatocyte growth factor through ERK, STAT3, and AKT in endothelial cells. Hypertension 37, 581-586 (2001)
8. Y.W. Zhang, G.F. Vande Woude, HGF/SF-met signaling in the control of branching morphogenesis and invasion. J. Cell. Biochem. 88, 408-417 (2003)
9. C.F. Gao, G.F. Vande Woude, HGF/SF-Met signaling in tumor progression. Cell Res. 15, 49-51 (2005)
10. M. Trovato, M. Grosso, E. Vitarelli, S. Benvenga, F. Trimarchi, G. Barresi, Immunoexpression of the hepatocyte growth factor (HGF), HGF- receptor (c-met) and STAT3 on placental tissues from malformed fetuses. Histol. Histopathol. 17, 691-698 (2002)
11. M. Trovato, E. Vitarelli, M. Grosso, S. Alesci, S. Benvenga, F. Trimarchi, G. Barresi, Immunohistochemical expression of HGF, c-met and transcription-factor STAT3 in colorectal tumors. Eur. J. Histochem. 48, 291-297 (2004)
12. R.M. Ruggeri, E. Vitarelli, G. Barresi, F. Trimarchi, S. Benvenga, M. Trovato, HGF/c-met system pathway in benign and malignant hystotypes of thyroid nodules: an immunohistochemical characterization. Histol. Histopathol. 27, 113-121 (2012)
13. S. Kim, B. Lee, H. Kim, J. Lee, Abstracts for the Eighth Congress of the European Association for Neuro-Oncology: met tyrosine kinase receptor expression in pituitary adenomas. Neurooncology 10, 1134 (2008)
14. X.Z. Hou, W. Liu, H.T. Fan, B. Liu, B. Pang, T. Xin, S.C. Xu, Q. Pang, Expression of hepatocyte growth factor and its receptor c-Met in human pituitary adenomas. Neurooncology 12, 799-803 (2010)
15. M. Musat, M. Korbonits, B. Kola, N. Borboli, M.R. Hanson, A.M. Nanzer, J. Grigson, S. Jordan, D.G. Morris, M. Gueorguiev, M. Coculescu, S. Basu, A.B. Grossman, Enhanced protein kinase B/Akt signalling in pituitary tumours. Endocr. Relat. Cancer 12, 423-433 (2005)
16. D. Dworakowska, E. Wlodek, C.A. Leontiou, S. Igreja, M. Cakir, M. Teng, N. Prodromou, M.I. Góth, S. Grozinsky-Glasberg, M. Gueorguiev, B. Kola, M. Korbonits, A.B. Grossman, Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors. Endocr. Relat. Cancer 16, 1329-1338 (2009)
17. C. Lu, M.C. Willingham, F. Furuya, S.Y. Cheng, Activation of phosphatidylinositol 3-kinase signalling promotes aberrant pituitary growth in a mouse model of thyroid-stimulating hormone-secreting pituitary tumors. Endocrinology 149, 3339-3345 (2008)
18. rd series, Fascicle 22. Washington: Armed Forces Institute of Pathology (1998)
19. S.L. Asa, Practical pituitary pathology what does the pathologist need to know? Arch. Pathol. Lab. Med. 132, 1231-1240 (2008)
20. S. Melmed, Pathogenesis of pituitary tumors. Nat. Rev. Endocrinol. 7, 257-266 (2011)
21. S. Cannavò, L. Curtò, S. Squadrito, B. Almoto, A. Vieni, F. Trimarchi, Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma. J. Endocrinol. Invest. 22, 354-359 (1999)
22. V. Vasilev, A.F. Daly, L. Vroonen, S. Zacharieva, A. Beckers, Resistant prolactinomas. J. Endocrinol. Invest. 34, 312-316 (2011)
23. T. Mancini, F.F. Casanueva, A. Giustina, Hyperprolactinemia and prolactinomas. Endocrinol. Metab. Clin. North Am. 37, 67-99 (2008)
24. S. Cannavò, S. Squadrito, L. Curtò, B. Almoto, A. Vieni, F. Trimarchi, Results of a two-year treatment with slow release lanreotide in acromegaly. Horm. Metab. Res. 32, 224-229 (2000)
25. A. Colao, G. Arnaldi, P. Beck-Peccoz, S. Cannavò, R. Cozzi, E. degli Uberti, L. De Marinis, E. De Menis, D. Ferone, V. Gasco, A. Giustina, S. Grottoli, G. Lombardi, P. Maffei, E. Martino, F. Minuto, R. Pivonello, E. Ghigo, Pegvisomant in acromegaly: why, when, how. J. Endocrinol. Invest. 30, 693-699 (2007)
26. A. Giustina, M.D. Bronstein, F.F. Casanueva, P. Chanson, E. Ghigo, K.K. Ho, A. Klibanski, S. Lamberts, P. Trainer, S. Melmed, Current management practices for acromegaly: an international survey. Pituitary 14, 125-133 (2011)
27. A. Giustina, G. Mazziotti, V. Torri, M. Spinello, I. Floriani, S. Melmed, Meta-analysis on the effects of octreotide on tumor mass in acromegaly. PLoS ONE 7, e36411 (2012)
28. T. Mancini, T. Porcelli, A. Giustina, Treatment of Cushing disease: overview and recent findings. Ther. Clin. Risk Manag. 21, 505-516 (2010)
29. S. Cannavò, B. Almoto, C. Dall'Asta, S. Corsello, R.M. Lovicu, E. De Menis, F. Trimarchi, B. Ambrosi, Long-term results of treatment in patients with ACTH-secreting pituitary macroadenomas. Eur. J. Endocrinol. 149, 195-200 (2003)
30. S. Cannavò, S. Squadrito, L. Curtò, B. Almoto, F. Trimarchi, Effectiveness of slow-release lanreotide in previously operated and untreated patients with GH-secreting pituitary macroadenoma. Horm. Metab. Res. 33, 618-624 (2001)
31. G. Vitale, M. Caraglia, P.M. van Koetsveld, P. Maroni, M. Marra, A. Colao, S.W. Lamberts, F. Cavagnini, L.J. Hofland, Potential role of type I interferons in the treatment of pituitary adenomas. Rev. Endocr. Metab. Disord. 10, 125-133 (2009)
32. H. Rubinfeld, I. Shimon, PI3K/Akt/mTOR and Raf/MEK/ERK signaling pathways perturbations in non-functioning pituitary adenomas. Endocrine 42, 285-291 (2012)
33. S.R. Sangeetha, N. Singh, J.R. Vender, K.M. Dhandapani, Suberoylanilide hydroxamic acid (SAHA) induces growth arrest and apoptosis in pituitary adenoma cells. Endocrine 35, 389-396 (2009)
34. Z.A. Syed, W. Yin, K. Hughes, J.N. Gill, R. Shi, J.L. Clifford, HGF/c-met/Stat3 signaling during skin tumor cell invasion: indications for a positive feedback loop. BMC Cancer. 11, 180 (2011)
35. R. Bu, S. Uddin, P. Bavi, A.R. Hussain, F. Al-Dayel, S. Ghourab, M. Ahmed, K.S. Al-Kuraya, HGF/c-Met pathway has a prominent role in mediating antiapoptotic signals through AKT in epithelial ovarian carcinoma. Lab. Invest. 91, 124-137 (2011)
36. G. Lahat, P. Zhang, Q.S. Zhu, K. Torres, M. Ghadimi, K.D. Smith, W.L. Wang, A.J. Lazar, D. Lev, The expression of c-Met pathway components in unclassified pleomorphic sarcoma/malignant fibrous histiocytoma (UPS/MFH): a tissue microarray study. Histopathology 59, 556-561 (2011)
37. S. Previdi, P. Maroni, E. Matteucci, M. Broggini, P. Bendinelli, M.A. Desiderio, Interaction between human-breast cancer metastasis and bone microenvironment through activated hepatocyte growth factor/Met and beta-catenin/Wnt pathways. Eur. J. Cancer 46, 1679-1691 (2010)
38. A. Menakongka, T. Suthiphongchai, Involvement of PI3K and ERK1/2 pathways in hepatocyte growth factor-induced cholangiocarcinoma cell invasion. World J. Gastroenterol. 16, 713-722 (2010)
39. Y. Miyata, Y. Sagara, S. Kanda, T. Hayashi, H. Kanetake, Phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor growth and prognosis in patients with bladder cancer: correlation with matrix metalloproteinase-2 and -7 and E-cadherin. Hum. Pathol. 40, 496-504 (2009)
40. R. Abounader, B. Lal, C. Luddy, G. Koe, B. Davidson, E.M. Rosen, J. Laterra, In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis. FASEB J. 16, 108-110 (2002)
41. L.M. Knowles, L.P. Stabile, A.M. Egloff, M.E. Rothstein, S.M. Thomas, C.T. Gubish, E.C. Lerner, R.R. Seethala, S. Suzuki, K.M. Quesnelle, S. Morgan, R.L. Ferris, J.R. Grandis, J.M. Siegfried, HGF and c-Met Participate in Paracrine Tumorigenic Pathways in Head and Neck Squamous Cell Cancer. Clin. Cancer Res. 15, 3740-3750 (2009)
42. J.R. Sierra, M.S. Tsao, c-MET as a potential therapeutic target and biomarker in cancer. Ther. Adv. Med. Oncol. 3, S21-S35 (2011)
43. K.M. Nicholson, N.G. Anderson, The protein kinase B/Akt signalling pathway in human malignancy. Cell. Signal. 14, 381-395 (2002)
44. Y.H. Min, J.I. Eom, J.W. Cheong, H.O. Maeng, J.Y. Kim, H.K. Jeung, S.T. Lee, M.H. Lee, J.S. Hahn, Y.W. Ko, Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: its significance as a prognostic variable. Leukemia 17, 995-997 (2003)
45. Y. Kubota, H. Ohnishi, A. Kitanaka, T. Ishida, T. Tanaka, Constitutive activation of PI3K is involved in the spontaneous proliferation of primary acute myeloid leukemia cells: direct evidence of PI3K activation. Leukemia 18, 1438-1440 (2004)
46. G. Vitale, S. Zappavigna, M. Marra, A. Dicitore, S. Meschini, M. Condello, G. Arancia, S. Castiglioni, P. Maroni, P. Bendinelli, R. Piccoletti, P.M. van Koetsveld, F. Cavagnini, A. Budillon, A. Abbruzzese, L.J. Hofland, M. Caraglia, The PPAR-γ agonist troglitazone antagonizes survival pathways induced by STAT-3 in recombinant interferon-β treated pancreatic cancer cells. Biotechnol. Adv. 30, 169-184 (2012)
47. J. Karar, A. Maity, PI3K/AKT/mTOR Pathway in Angiogenesis. Front. Mol. Neurosci. 4, 51 (2011)
48. J.F. Sun, T. Phung, I. Shiojima, T. Felske, J.N. Upalakalin, D. Feng, T. Kornaga, T. Dor, A.M. Dvorak, K. Walsh, L.E. Benjamin, Microvascular patterning is controlled by fine-tuning the Akt signal. PNAS 102, 128-133 (2005)